Furthermore, patients with ESCC showing strong and diffuse MTH1 immunoreactivity had higher cancer stage (Table 1) and showed poorer prognosis than those showing weak and focal MTH1 immunoreactivity (Fig. 3). The gene discussed is NUDT1; the disease is esophageal squamous cell carcinoma.